The estimated Net Worth of Bruce C Cozadd is at least $103 Million dollars as of 1 February 2023. Mr. Cozadd owns over 1,000 units of Jazz Pharmaceuticals plc stock worth over $38,590,910 and over the last 21 years he sold JAZZ stock worth over $49,647,069. In addition, he makes $14,713,600 as Chairman of the Board und Chief Executive Officer at Jazz Pharmaceuticals plc.
Bruce has made over 108 trades of the Jazz Pharmaceuticals plc stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of JAZZ stock worth $155,790 on 1 February 2023.
The largest trade he's ever made was exercising 836,971 units of Jazz Pharmaceuticals plc stock on 11 January 2012 worth over $12,797,287. On average, Bruce trades about 8,703 units every 27 days since 2003. As of 1 February 2023 he still owns at least 367,078 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Mr. Cozadd stock trades at the bottom of the page.
Bruce C. Cozadd serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Bruce C. Cozadd has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012, and from October 2019 through March 2020, he served as our interim principal financial officer. Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. and has served as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.’s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation, he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. He serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. Mr. Cozadd previously served on the boards of directors of Cerus Corporation from 2001 to January 2018 and Threshold Pharmaceuticals, Inc. from 2005 to August 2017. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
As the Chairman of the Board und Chief Executive Officer of Jazz Pharmaceuticals plc, the total compensation of Bruce Cozadd at Jazz Pharmaceuticals plc is $14,713,600. There are no executives at Jazz Pharmaceuticals plc getting paid more.
Bruce Cozadd is 56, he's been the Chairman of the Board und Chief Executive Officer of Jazz Pharmaceuticals plc since 2009. There are 13 older and 14 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
Bruce's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright und Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: